XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Breast Channel
subscribe to Breast newsletter

Latest Research : Cancer : Breast

   DISCUSS   |   EMAIL   |   PRINT
TAC Better than FAC for Early Breast Cancer
Jun 3, 2005, 10:28, Reviewed by: Dr.

The researchers concluded that the chemotherapy regimen TAC improves cancer-free and overall survival compared to FAC as adjuvant therapy in node-positive breast cancer.

 
According to a recent article published in the New England Journal of Medicine, the chemotherapy combination referred to as TAC (Taxotere�, Adriamycin�, and Cytosar�) improves cancer-free and overall survival compared to treatment with FAC (5-Fluorouracil, Adriamycin�, and Cytosar�) in early breast cancer.

Early breast cancer refers to cancer that has not spread to distant sites in the body. However, in early breast cancer, there may be cancer spread to lymph nodes under the arm (axillary), referred to as node-positive breast cancer. Standard treatment for node-positive breast cancer typically includes the surgical removal of the cancer, radiation therapy and chemotherapy. The use of chemotherapy following surgery, referred to as adjuvant chemotherapy, is utilized to kill any cancer cells that may be remaining in the body following surgery. The optimal adjuvant chemotherapy regimen in node-positive breast cancer patients continues to be evaluated. FAC is becoming a commonly used adjuvant chemotherapy regimen in breast cancer; however, the chemotherapy agent Taxotere has demonstrated promising results in the treatment of this disease.

Researchers affiliated with the Breast Cancer International Research Group 001 Investigators conducted a clinical trial to directly compare the chemotherapy regimens TAC to FAC as adjuvant therapy in women with node-positive breast cancer. This trial included 1,491 women who were treated with surgery followed by either TAC or FAC. At 5 years, disease-free survival was 75% among patients treated with TAC, compared with 68% among patients treated with FAC. Overall survival at 5 years was 87% for those treated with TAC, compared with 81% for those treated with FAC. Low levels of white blood cells accompanied by fever (febrile neutropenia) were significantly higher in the group of patients treated with TAC versus those treated with FAC (24.7% and 2.5%, respectively); however, infection rates remained low in both groups of patients. Quality of life was reported as being diminished during treatment in patients treated with TAC, however, this was returned to normal following completion of therapy.

The researchers concluded that the chemotherapy regimen TAC improves cancer-free and overall survival compared to FAC as adjuvant therapy in node-positive breast cancer. Although quality of life was diminished during treatment with TAC, it returned to normal following completion of treatment. Patients diagnosed with early breast cancer who are to undergo treatment with chemotherapy may wish to speak with their physician regarding their individual risks and benefits of treatment with TAC.
 

- New England Journal of Medicine. 2005;352:2302-2313
 

cancerconsultants.com

 
Subscribe to Breast Newsletter
E-mail Address:

 

Reference: Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. New England Journal of Medicine. 2005;352:2302-2313.

Related Breast News

Breast cancer chemotherapy may deterioration in cognitive function
Elderly Breast Cancer Patients May Be Under-Diagnosed And Under-Treated
Tissue Geometry Plays Crucial Role in Breast Cell Invasion
Ethnic variations in hormone levels may cause differences in breast cancer risk
Researchers set benchmarks for screening mammography
Raloxifene Reduces Breast Cancer Risk in Postmenopausal Women at All Risk Levels
Physical activity improves survival in breast cancer patients
Pedigree assessment tool correctly identifies women with higher risk of breast cancer
MRI more accurately determines cancer spread into breast ducts
Core needle biopsy gives an accurate picture of gene expression


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us